Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 8/20 | 0.42 |
| ▸ | MAOA | P21397 | 5/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.38 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.38 |
| ▸ | PRKX | P51817 | 1/20 | 0.37 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | HRH1 | P35367 | 1/20 | 0.35 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.34 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4508467 | 0.92 | S1PR1 (0.37) | MAOBMAOAS1PR1S1PR5PIM1 | |
| SCHEMBL4525516 | 0.88 | MRGPRX4 (0.44) | MAOBMAOAS1PR1S1PR5PIM1 | |
| SCHEMBL13674513 | 0.87 | HSD11B1 (0.40) | S1PR1ACVR1HSD11B1 | |
| SCHEMBL14365300 | 0.86 | MAOB (0.39) | MAOBMAOAS1PR1S1PR5PIM1 | |
| SCHEMBL4517259 | 0.85 | HSD11B1 (0.40) | ACVR1HSD11B1CYP2C9ADRA1AHRH1 | |
| SCHEMBL13674534 | 0.85 | HSD11B1 (0.40) | ACVR1HSD11B1CYP2C9ADRA1AHRH1 | |
| SCHEMBL4514955 | 0.85 | S1PR1 (0.40) | MAOBMAOAS1PR1ACVR1HSD11B1 | |
| SCHEMBL4514405 | 0.85 | S1PR1 (0.39) | MAOBMAOAS1PR1S1PR5PRKX | |
| SCHEMBL5547531 | 0.84 | HSD11B1 (0.40) | MAOBMAOAS1PR1S1PR5PIM1 | |
| SCHEMBL13674485 | 0.84 | OPRM1 (0.39) | HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-22 | — | — | US | disclosed |
| EP-1864971-A1 | PROPHYLACTIC/THERAPEUTIC AGENT FOR DIABETES | Takeda Pharmaceutical Company Limited (JP) | 2007-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | HSD11B1, HSD17B1, HSD11B2 | MAOB 2109/4885MAOA 1927/4885S1PR1 521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.